The IL1R1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the 143B human osteosarcoma cell line, with targeted disruption of the IL1R1 gene. IL1R1 encodes the type I interleukin-1 receptor, which initiates pro-inflammatory signaling upon binding IL-1?? or IL-1??. The polyclonal format provides a heterogeneous pool of edited cells, enhancing reproducibility in loss-of-function studies. This product is supplied as a ready-to-use cellular model for investigating IL-1-mediated pathways in bone cancer research.
The 143B cell line is a highly metastatic osteosarcoma model originally derived from the HOS line. It is widely utilized for studying molecular mechanisms of tumorigenesis, metastasis, and the bone tumor microenvironment. Given its aggressive phenotype and expression of inflammatory signaling components, 143B offers a stringent and relevant background for examining the role of IL1R1 in a malignancy where inflammatory cytokines are thought to influence progression and dissemination.
IL1R1 functions by binding IL-1?? or IL-1??, then heterodimerizing with the accessory protein IL1RAP. This complex recruits adaptor MYD88 and kinases IRAK1 and IRAK4, which signal through TRAF6 to activate NF-??B (NFKB1, RELA) and MAPK (MAPK8/JNK, MAPK14/p38) pathways. These cascades drive transcription factors FOS and JUN, inducing expression of pro-inflammatory targets such as IL6, IL8, PTGS2, and MMP9. Negative regulators like TOLLIP modulate signal output. Disruption of IL1R1 ablates this entire signaling axis, creating a tool to study IL-1-dependent biology.
In osteosarcoma, IL-1 signaling is implicated in promoting invasiveness, metastasis, and osteolytic bone destruction. The knockout cells allow dissection of autocrine and paracrine IL-1 effects on tumor cell migration and secretion of factors like MMP9 and IL-8. They also facilitate studies of inflammatory cross-talk with TNF-?? or LPS, and of IL-1??s role in mechanisms resembling deficiency of the IL-1 receptor antagonist (DIRA). This model is well-suited for exploring IL-1-independent compensatory pathways and for direct comparison with pharmacological blockade.
Key applications include Western blotting for phosphorylated RELA, JNK, and p38; NF-??B luciferase reporter assays; RT-qPCR for downstream gene expression; flow cytometry for loss of surface IL1R1; and ELISA-based quantification of secreted IL-6 and IL-8. Transwell migration and invasion assays quantify metastatic propensity, while xenograft models assess in vivo dissemination. The cells also enable drug sensitivity testing with IL-1 pathway inhibitors, including biologics and small-molecule antagonists. For additional information, please contact Ascent Research.
